Randomized Double-Blind Placebo-Controlled Trial Evaluating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Phase 3
550
about 2.7 years
18+
16 sites in AZ, CA, CO +11
About this study
Researchers are testing whether baricitinib, compared to a placebo, improves neurological function, physical function, quality of life, and other symptoms in people with Long COVID. The trial will last for 983 days and involve approximately 550 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Baricitinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
baricitinib
oral (Oral Tablet)
Secondary: Cognitive participant-reported outcomes using the PROMIS-Cognitive Function-Short Form 8a at 1-, 3-, 6-, and 12-months, Exercise capacity including the 6-minute walk test (6MWT) at 6- and 12-months, General participant-reported outcomes using the PROMIS-29 at 1-, 3-, 6-, and 12-months, Post COVID-19 symptom burden including the Symptom Burden Questionnaire for Long COVID (SBQ-LC) Circulation Subscale at 1-, 3-, 6-, and 12-months, Post-exertional malaise including the modified De Paul Symptom Questionnaire - Post-Exertional Malaise (mDSQ-PEM) at 6- and 12-months, Quality-of-life measures including the EuroQOL-5D-5L at 3-, 6-, and 12-months
Infectious